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New Approaches in the Use of CycIosporine: 
With Particular Reference to the Liver 
T.E. Starzl 
T HE REVOLUTIONARY influence of 
cyclosporine (esA) on liver transplanta-
tion is so well known l that another article with 
this message would be a superfluity. Thus, I 
will talk about our clinical experience only 
briefly, and then mention some potential 
future developments that could involve esA in 
one way or another. 
THE CLINICAL IMPACT OF CYCLOSPORINE 
Six weeks ago, Iwatsuki et at2 summarized 
at a meeting in Pittsburgh the results with our 
first 1,000 liver recipients in the so-called esA 
era. Life-survival was compared with that of 
170 historical controls in whom treatment was 
with azathioprine (or cyclophosphamide) and 
prednisone, usually with antilymphocyte glob-
ulin (ALG). 
The life-survival curve of patients before 
esA-steroid therapy showed steep early losses 
so that <1/3 of patients entered (56 of 170) 
were living at the end of 1 year. Deaths 
beyond 1 year continued to occur so that at 5 
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years only 21% were still living (Fig 1). Now, 
with follow-upsof7 to 18 years, 28 (16.5%) of 
the original 170 recipients are still alive. 
The I-year survival with the introduction of 
esA in early 1980 was almost immediately 
doubled. The I-year advantage gained has not 
been diluted by the further passage of time, as 
judged by actual or actuarial statistics. At 3 
years and at 5 years, the projected survival has 
tripled. Thus, the gap is increasing with each 
year of further followup. 
These improved results were obtained in 
spite of the inclusion for candidacy of an 
increasing number of high-risk recipients 
including older patients who were systemati-
cally excluded until 1984 and 1985 if they 
were over 50 years of age. In Fig 2, a year by 
year account is given of patients undergoing 
liver transplantation beyond the age of 50. By 
1986, almost 35% were in the older age group. 
Similarly, age restrictions at the lower end 
were all but eliminated. Our youngest recip-
ient was only 26 days old. 
LIMITATIONS OF CYCLOSPORINE 
In spite of its great value, esA has two 
limitations that have some relationship to 
each other. First, the drug's nephrotoxicity 
imposes a dose ceiling. This was surprising in 
the first clinical trials, since renal injury had 
not been a striking feature of toxicologic stud-
ies in rats, dogs, or rabbits. The practical 
consequence has been that esA has been used 
most efficiently as part of a pharmacologic 
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Fig 1. Actuarial survival rates of 1,000 patients 
treated with CsA/steroid therapy compared with suriv-
ial of 170 patients treated with the "conventional" 
therapy used before 1980. 
co~ktailI combining it with steroids, azathio-
pnne, or lymphoid-depleting procedures in-
cluding ALG or thoracic duct drainage. l The 
principle has been to reduce the specific toxic-
ity of individual drugs by using them in 
smaller amounts. To be effective, this strategy 
requires that the different drugs in a regimen 
be at least additive, and optimally they should 
be synergistic. 
Perhaps all rejections could be controlled if 
CsA could be administered without dose 
restriction. However, with the regimens that 
have been evolved, rejections ranging from 
annoying to irreversible have been seen with 
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Fig 2. Liver transplantation in adults. Change in 
pattern of age distribution with recent increased num-
bers of older recipients. Note that the data for 1986 was 
for only the first nine months. 
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the kidney, liver, and other transplanted 
organs. Thus, failure to control rejection in all 
cases is the second limitation. 
There is no reason to think that CsA is the 
last development that will occur in immuno-
suppression, and in fact, other candidates are 
already lurking in the wings. I will next talk 
about how research with CsA has paved the 
way for a search for other drugs, and then I 
will discuss briefly the most promising of these 
new agents (FK 506) as it could relate to liver 
transplantation or the transplantation of other 
organs in the future. 
IN VITRO STUDIES 
When CsA was developed, more was 
accomplished than the mere production of a 
new and eminently practical agent. Possibly 
even more importantly, powerful new tech-
niques were developed that made it possible in 
test tubes or culture media to dissect the 
mechanisms of drug action as these affected 
lymphocyte population; to study the intrinsic 
cytotoxicity of the agents on cell cultures; and 
to measure in highly quantifiable test systems 
the interactions (including synergism) of dif-
ferent drugs. These techniques have made it 
possible with a few days of effort to acquire 
information that previously was completely 
inaccessible or that required years to accumu-
late. 
Zeevi and Duquesnoy in Pittsburgh have 
referred to these techniques as mini-trans-
plant models.3•s From biopsies of hearts and 
livers, they obtained clones of primed lympho-
cytes that had been exposed to donor-specific 
antigen by virtue of transplantation (Fig 3). 
When donor spleen, which is saved at the time 
of organ harvest and preserved, is added to the 
recipient lymphocyte culture, the "primed" 
recipient lymphocytes proliferate (cell expan-
sion) with very little delay (Fig 4). The mech-
ani~ms of the expansion can be studied quali-
tatIvely and quantatively by collecting 
interleukin 2 (IL2) or other lymphokines from 
the culture medium and adding them to IL2-
dependent cells. The proliferation or other 
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Fig 3. Propagation of activated lymphocytes from 
human biopsies with interleukin. 
response characteristics of these IL2-depen-
dent cells provide an end point for a biologic 
assay. 
The ability of CsA or other drugs to prevent 
this expansion of a human lymphocyte popu-
lation is illustrated in Fig 5. In the liver or 
heart biopsies of patients undergoing severe or 
even intractable rejection, clones have been 
found of CsA resistant lymphocytes side-by-
side with sensitive clones (Fig 6).6 In such 
cases, the new experimental agent, FK 506 
(Fujisawa Pharmaceutical Co, Ltd, Osaka, 
Japan), about which I will say more in a 
moment, used alone or added to CsA, can 
eliminate the rogue clones (Fig 7).7 It is 
fascinating that CsA, azathioprine, and FK 
506 are all synergistic with each other with in 
vitro7,8 or in vivo models.9• 11 FK 506 and CsA 
have an identical or at least almost identical, 
mechanism, namely inhibition of the produc-
tion of IL2.8•12 
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Fig 4. Lymphocyte culture technique in which 
human lymphocytes obtained from biopsies and cul-
tured are exposed to donor cells. Clonal expansion 
results. 
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Fig 5. Prevention or inhibition of clonal expansion 
in primed human lymphocyte cultures by eddition of 
CsA or other drugs. 
IN VIVO STUDIES OF NEW DRUGS AND 
COMBINATIONS 
As already mentioned, the most promising 
of the new drugs is FK 506. This agent, which 
is derived from a strain of Streptomyces, was 
reported verbally by Ochiai et al 12 in Helsinki 
in August 1986. This first description of FK 
506's remarkable immunosuppressive proper-
ties was published only 8 months ago. 12 Yet, a 
complete symposium of all that is known of 
FK 506 was held in Gothenburg, Sweden, by 
June 1987 and published in a special volume 
of Transplantation Proceedings in October 
1987. 13 
In rats submitted to ACI to Lewis hetero-
topic heart transplantation, the control of 
rejection with FK 506 has been reliable and 
. h l' I .. 9 12 14 Wit Itt e toxIcity." FK 506 is synergistic 
in rats with CsA alone and with CsA plus low 
doses of steroids.9 Partial tolerance induction 
or something resembling it, has been mad; 
possible with only three daily doses of FK 506 
injected four, five, and six days after trans-
plantation.9,1) 
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Fig 6. Development of CsA-resistant clones in liver 
or heart biopsies that were undergoing clinical rejec-
tion. 
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Fig 7. Disappearance of "rogue" clones by the 
addition of the experimental drug FK 506. 
FK 506 is toxic in dogs, causing lethal 
emaciation and wide-spread vasculitis. In 
spite of this, the results with canine renal and 
hepatic transplantation have been comparable 
with those with CsA. Using CsA and FK 506 
together, with or without small doses of ste-
roids, the best results ever obtained with 
canine renal transplantation have been 
reported by Todo et al. 10.11 
Transplantation studies in cynomolgus 
monkeys and in baboons are underway as a 
last step in deciding if clinical trials are justi-
fied and if so, how to engage in these. It is our 
present expectation that CsA and low doses of 
FK 506 will be used together, with or without 
small doses of steroids. With this combina-
tion, the limiting factors of nephrotoxicity and 
refractory rejection that exist with the present 
day use of CsA could become a thing of the 
past. Whether these are realistic predictions 
or merely expressions of hope remains to be 
seen. 
OTHER USES OF LIVER TRANSPLANTATION 
Liver transplantation has profoundly af-
fected the practice of hepatology. The indica-
tions for liver replacement are like a table of 
contents for atextbook of liver disease, in that 
any lethal, non-neoplastic disorder constitutes 
a potential reason for orthotopic liver trans-
plantation. The great burst of both application 
and acceptance of this procedure is undoubt-
edly over, but perhaps exciting times are still 
ahead. In a recent inquiry by an Italian jour-
nalist, the question was posed "Do you think 
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that in the next decade a 'puzzle man' with 
heart, liver, and pancreas taken from other 
human beings might be feasible?" The answer 
is that there are already numerous examples 
of puzzle men and women who have received a 
heart and kidney, a pancreas and kidney, a 
heart and lungs, a liver and kidney, and even a 
heart and liver. The increasing boldness with 
which transplantation is being developed 
makes it certain that other and more compli-
cated combinations will be forthcoming in the 
near future. 
Last week, an ancient operation developed 
more than a quarter of a century ago in dogs, IS 
was pulled from the moth balls and used to 
treat a 3-year-old child who had lost all of her 
intestines from a perinatal midgut volvulous. 
After 3 years of parenteral hyperalimenta-
tion, the patient had developed hepatic fail-
ure. Now weighing 35 pounds, she was given a 
new stomach, small bowel, colon, liver, and 
pancreas in continuity from an 8-pound donor. 
This recipient has done well so far in a clinical 
trial that would have been inconceivable only 
a few years ago without the improved immu-
nosuppression made possible by the CsA with 
which she is being treated, together with 
prednisone. 
A threat of unknown seriousness for this 
child is graft-v-host (GvH) reaction in which 
the lymphoid tissue transferred by the multi-
visceral graft could prove to be a lethal instru-
ment directed against the recipient. Serious 
GvH reactions have been seen in recipients 
given livers as reported by Burdick et al 16 at 
the lohns Hopkins Hospital and in our own 
institution, but this has been a rare complica-
tion of liver transplantation alone. It is to be 
expected that very effective immunosuppres-
sive therapy given for the purpose of prevent-
ing classical rejection could also keep a GvH 
reaction at bay. 
SUMMARY 
Liver transplantation in the highly practi-
cal form that exists today has been made 
possible by multiple agent immunosuppres-
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sion of which the most important component 
is CsA. Present day practices of immunosup-
pression are certain to be changed and proba-
bly in the near future in order to increase the 
effectiveness of therapy and to reduce the 
nephrotoxicity and other side-effects that 
until now have inhibited further applications. 
The introduction of new drugs such as FK 
T.E.STARZL 
506, some of which are clearly synergistic 
with CsA, could ameliorate past problems 
with drug toxicity. With such improvements, 
and possibly even with more clever use of 
therapy that already is available, wider and 
more complex use of liver transplantation will 
be possible. 
-. REFERENCES_ 
1. Starzl TE, Iwatsuki S. Van Thiel DH, et al: Hepa-
tology 2:614. 1982 
2. Iwatsuki S, Starzl TE, Todo S, et al: Transplant 
Proc 20:498, 1988 (suppl I) 
3. Zeevi A, Fung J. Zerbe T, et al: Transplantation 
41 :620, 1986 
4. Fung J. Zeevi A, Starzl TE, et al: Hum Immunol 
16:182.1986 
5. Duquesnoy R, Weber T, Zeevi A, et al: Transplant 
Proc 20:772. 1988 (suppl I) 
6. Zeevi A, Venkataramanan R, Burckart G, et al: 
Hum Immuno121:143, 1988 
7. Zeevi A, Duquesnoy R, Eiras G, et al: Transplant 
Proc 19:40, 1987 (suppl 6) 
8. Zeevi A, Eiras G, Rabinowich H, et al: Transplant 
Proc 20:220, 1988 (suppl 1) 
9. Murase N, Todo S, Lee P, et al: Transplant Proc 
19:71,1987 (suppI6) 
10. Todo S. Demetris AJ. Ueda Y, et al: Transplant 
Proc 19:57.1987 (suppI6) 
II. Todo S. Murase N. Ueda Y. et al: Transplant Proc 
20:2 IS, 1988 (suppl I) 
12. Ochai T, Nakajima K, Nagata M. et al: Trans-
plant Proc 19:1284, 1987 
13. Starzl TE, Todo S, Makowka L (eds): Transplant 
Proc 19. 1987 (suppl 6) 
14. Lee P, Murase N, Todo S, et al: Surg Res Com-
mun 1:325, 1987 
IS. Starzl TE, Kaupp HA Jr, Brock DR, et al: Am J 
Surg 103:219, 1962 
16. Burdick JF. Vogelsang GB, Smith WJ, et al: N 
Engl J Med 318:689,1988 (supplll) 
